You just read:

Neurocrine Announces FDA Approval of INGREZZA™ (valbenazine) Capsules as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD) (with multimedia)

News provided by

Neurocrine Biosciences, Inc.

Apr 11, 2017, 17:37 ET